Barinthus Biotherapeutics plc
NASDAQ Global MarketTotal Valuation
Barinthus Biotherapeutics plc carries a market capitalization of 30.23M, placing it among publicly traded companies globally. Its enterprise value stands at -21.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 30.23M |
| Enterprise Value | -21.98M |
Share Statistics
Barinthus Biotherapeutics plc currently has 40.85M shares outstanding.
| Shares Outstanding | 40.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | -1.02 |
| P/OCF Ratio | -1.02 |
Financial Position
Barinthus Biotherapeutics plc maintains a current ratio of 5.54, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.02, indicating elevated leverage, while an interest coverage ratio of -660.85 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.54 |
| Quick Ratio | 5.33 |
| Debt / Equity | 18.02 |
| Debt / EBITDA | -0.29 |
| Interest Coverage | -660.85 |
Financial Efficiency
| Return on Equity (ROE) | -52.39 |
| Return on Assets (ROA) | -39.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -167,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Barinthus Biotherapeutics plc's stock has declined approximately -29.51429% over the past 52 weeks. The 50-day moving average sits at 0.63, while the 200-day moving average is 0.66.
| Beta (5Y) | N/A |
| 52-Week Price Change | -29.51429% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.66 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -35.02M, while operating income came in at -38.51M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -38.51M |
| Pretax Income | -41.97M |
| Net Income | -41.77M |
| EBITDA | -35.02M |
| EBIT | -38.51M |
| Earnings Per Share (EPS) | -1.03 |
Balance Sheet
Barinthus Biotherapeutics plc holds 59.30M in cash and equivalents against 10.30M in total debt, resulting in a net debt position of -59.29M. Total book value stands at 57.07M, with working capital of 51.85M providing operational flexibility.
| Cash & Cash Equivalents | 59.30M |
| Total Debt | 10.30M |
| Net Debt | -59.29M |
| Equity (Book Value) | 57.07M |
| Book Value Per Share | 1.40 |
| Working Capital | 51.85M |
Cash Flow
Barinthus Biotherapeutics plc produced -26.42M in operating cash flow over the past twelve months.
| Operating Cash Flow | -26.42M |
| Capital Expenditures | N/A |
| Free Cash Flow | -26.42M |
| FCF Per Share | -0.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -98.17 |
Scores
Barinthus Biotherapeutics plc posts an Altman Z-Score of -6.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.80 |